Should I buy or sell Acurx Pharmaceuticals stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Acurx Pharmaceuticals in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ACXP shares. View ACXP analyst ratings or view top-rated stocks .

What is Acurx Pharmaceuticals' stock price target for 2024?

1 Wall Street analysts have issued twelve-month price objectives for Acurx Pharmaceuticals' stock. Their ACXP share price targets range from $12.00 to $12.00. On average, they expect the company's share price to reach $12.00 in the next twelve months. This suggests a possible upside of 566.7% from the stock's current price. View analysts price targets for ACXP or view top-rated stocks among Wall Street analysts .

How have ACXP shares performed in 2024?

Acurx Pharmaceuticals' stock was trading at $3.83 on January 1st, 2024. Since then, ACXP shares have decreased by 53.0% and is now trading at $1.80. View the best growth stocks for 2024 here .

Are investors shorting Acurx Pharmaceuticals?

Acurx Pharmaceuticals saw a increase in short interest in March. As of March 31st, there was short interest totaling 337,400 shares, an increase of 14.6% from the March 15th total of 294,500 shares. Based on an average daily volume of 169,100 shares, the days-to-cover ratio is presently 2.0 days. Approximately 2.8% of the company's shares are short sold. View Acurx Pharmaceuticals' Short Interest .

When is Acurx Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024. View our ACXP earnings forecast .

How were Acurx Pharmaceuticals' earnings last quarter?

Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) announced its quarterly earnings results on Friday, March, 15th. The company reported ($0.38) EPS for the quarter, missing the consensus estimate of ($0.26) by $0.12.

When did Acurx Pharmaceuticals IPO?

Acurx Pharmaceuticals (ACXP) raised $15 million in an IPO on Friday, June 25th 2021. The company issued 2,500,000 shares at $5.00-$7.00 per share. Alexander Capital, L.P. and Network 1 Financial Securities served as the underwriters for the IPO.

Who are Acurx Pharmaceuticals' major shareholders?

Acurx Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include NBC Securities Inc. (0.09%). Insiders that own company stock include Carl Sailer , David P Luci and Robert J Deluccia . View institutional ownership trends .

How do I buy shares of Acurx Pharmaceuticals?

Shares of ACXP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:ACXP

Acurx Pharmaceuticals (ACXP) Stock Price, News & Analysis

→ He Is Giving Away Bitcoin (From Crypto Swap Profits) (Ad)

Free ACXP Stock Alerts

$1.80

+0.14 (+8.43%)

(As of 04/17/2024 ET)

Compare

Today's Range: $1.62
▼
$1.84
50-Day Range: $1.64
▼
$3.25
52-Week Range: $1.17
▼
$8.82

Volume: 114,332 shs
Average Volume: 163,854 shs
Market Capitalization: $28.37 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $12.00

Get Acurx Pharmaceuticals alerts:

Acurx Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 566.7% Upside
$12.00 Price Target
Short Interest: Healthy
2.83% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.22
Based on 3 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($0.97) to ($2.30) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.76 out of 5 stars

Medical Sector

662nd out of 914 stocks

Pharmaceutical Preparations Industry

291st out of 406 stocks

3.5

Analyst's Opinion

Consensus Rating
Acurx Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Acurx Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
2.83% of the float of Acurx Pharmaceuticals has been sold short.
Short Interest Ratio / Days to Cover
Acurx Pharmaceuticals has a short interest ratio ("days to cover") of 2, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Acurx Pharmaceuticals has recently increased by 14.57%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Acurx Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Acurx Pharmaceuticals does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ACXP.

2.3

News and Social Media Coverage

News Sentiment
Acurx Pharmaceuticals has a news sentiment score of 0.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.40 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for Acurx Pharmaceuticals this week, compared to 1 article on an average week.
Search Interest
Only 6 people have searched for ACXP on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days.
MarketBeat Follows
3 people have added Acurx Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Acurx Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
35.30% of the stock of Acurx Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 11.53% of the stock of Acurx Pharmaceuticals is held by institutions.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Acurx Pharmaceuticals are expected to decrease in the coming year, from ($0.97) to ($2.30) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Acurx Pharmaceuticals is -1.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Acurx Pharmaceuticals is -1.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Acurx Pharmaceuticals has a P/B Ratio of 5.29. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Wall Street Star

This Apple-like Innovator is Revolutionizing Healthcare

AI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.

Click here to learn more about the booming eHealth industry

About Acurx Pharmaceuticals Stock (NASDAQ:ACXP)

Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase IIa clinical trial to treat patients with clostridium difficile infections. It is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia. The company was incorporated in 2017 and is headquartered in Staten Island, New York.

ACXP Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ACXP Stock News Headlines

April 17, 2024 | nasdaq.com

Acurx Pharmaceuticals Rings the Closing Bell

April 14, 2024 | americanbankingnews.com

Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Short Interest Update

April 17, 2024 | Priority Gold (Ad)

Biden to Launch “FedNOW” [Move Your Money Now]

Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentially cancel your money. You see Biden and the Fed have teamed up to create a controllable, traceable, programmable digital currency to replace the dollar...

April 12, 2024 | americanbankingnews.com

Acurx Pharmaceuticals (NASDAQ:ACXP) Shares Up 0.5%

March 20, 2024 | seekingalpha.com

Acurx Pharmaceuticals, Inc. (ACXP) Q4 2023 Earnings Call Transcript

March 19, 2024 | markets.businessinsider.com

Acurx Pharmaceuticals: Strong Buy on Ibezapolstat’s Promising Phase 3 Trials and Strategic Partnerships

March 19, 2024 | finance.yahoo.com

Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Q4 2023 Earnings Call Transcript

March 19, 2024 | finance.yahoo.com

Q4 2023 Acurx Pharmaceuticals Inc Earnings Call

April 17, 2024 | Wall Street Star (Ad)

This Apple-like Innovator is Revolutionizing Healthcare

March 18, 2024 | investorplace.com

ACXP Stock Earnings: Acurx Pharmaceuticals Misses EPS for Q4 2023

March 18, 2024 | finance.yahoo.com

We Think Acurx Pharmaceuticals (NASDAQ:ACXP) Needs To Drive Business Growth Carefully

March 18, 2024 | prnewswire.com

Acurx Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update

March 4, 2024 | prnewswire.com

Acurx Pharmaceuticals, Inc. to Discuss Fourth Quarter and Full Year 2023 Financial Results on March 18, 2024 Conference Call and Provide Business Update

February 27, 2024 | finance.yahoo.com

Acurx Announces FDA Has Granted an End of Phase 2 Meeting for Ibezapolstat for C. difficile Infection and the European Medicines Agency Granted SME Designation for Ibezapolstat EU Development

February 27, 2024 | prnewswire.com

Acurx Announces FDA Has Granted an End of Phase 2 Meeting for Ibezapolstat for C. difficile Infection and the European Medicines Agency Granted SME Designation for Ibezapolstat EU Development

February 17, 2024 | finance.yahoo.com

ACXP Mar 2024 4.000 call

February 16, 2024 | finance.yahoo.com

ACXP Mar 2024 5.000 put

February 2, 2024 | finance.yahoo.com

New to The Street Announces its 553rd Episode TV Line Up, Featuring Five Corporate Guests, Airing on the FOX Business Network, Monday, February 5, 2024, 10:30 PM PT

February 1, 2024 | finance.yahoo.com

New to The Street TV Announces Episode #552 with its Five Business Guest Interviews, Airs on Bloomberg TV as Sponsored Programming, Tonight, February 1, 2024, at 9:30 PM PT

January 26, 2024 | finance.yahoo.com

New to The Street Announces Episode 551, Five Corporate Interviews, Airing on the FOX Business Network, Monday, January 29, 2024, at 10:30 PM PT

January 23, 2024 | finance.yahoo.com

Acurx Pharmaceuticals to Present at the Microcap Conference, January 31, 2024 - February 1, 2024

January 17, 2024 | msn.com

Acurx stock plunges 26% amid Phase 2 data release for C. diff drug

January 17, 2024 | msn.com

ELAB, KIND and RLX among pre-market losers

January 17, 2024 | markets.businessinsider.com

Acurx Announces Positive Microbiology And Microbiome Data For Ibezapolstat From Phase 2b Trial

January 5, 2024 | finance.yahoo.com

New to The Street Announces its Four Corporate Interviews, Episode 543, Airing on the Fox Business Network, Monday, January 8, 2024, at 10:30 PM PT

January 3, 2024 | finance.yahoo.com

Acurx to present at the 42nd Annual J.P. Morgan Healthcare Conference

December 28, 2023 | benzinga.com

Acurx Pharmaceuticals Stock (NASDAQ:ACXP), Guidance and Forecast

See More Headlines

Receive ACXP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Acurx Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/15/2024
Today: 4/17/2024
Next Earnings (Estimated): 5/10/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:ACXP
CUSIP: N/A
CIK: 1736243
Web: www.acurxpharma.com
Phone: 917-533-1469
Fax: N/A
Employees: 4
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $12.00
High Stock Price Target: $12.00
Low Stock Price Target: $12.00
Potential Upside/Downside: +610.1%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.15)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-14,580,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -289.69%
Return on Assets: -185.19%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 2.53
Quick Ratio: 2.53

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.34 per share
Price / Book: 4.97

Miscellaneous

Outstanding Shares: 15,760,000
Free Float: 10,195,000
Market Cap: $26.63 million
Optionable: Optionable
Beta: -1.90

(Almost) Everything You Need To Know About The EV Market

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

Mr. Robert J. DeLuccia (Age 78)
Co-Founder & Executive Chairman
Comp: $701.54k

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

ACXP Stock Analysis - Frequently Asked Questions

Should I buy or sell Acurx Pharmaceuticals stock right now?: 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Acurx Pharmaceuticals in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ACXP shares.
View ACXP analyst ratings or view top-rated stocks.
What is Acurx Pharmaceuticals' stock price target for 2024?: 1 Wall Street analysts have issued twelve-month price objectives for Acurx Pharmaceuticals' stock. Their ACXP share price targets range from $12.00 to $12.00. On average, they expect the company's share price to reach $12.00 in the next twelve months. This suggests a possible upside of 566.7% from the stock's current price.
View analysts price targets for ACXP or view top-rated stocks among Wall Street analysts.
How have ACXP shares performed in 2024?: Acurx Pharmaceuticals' stock was trading at $3.83 on January 1st, 2024. Since then, ACXP shares have decreased by 53.0% and is now trading at $1.80.
View the best growth stocks for 2024 here.
Are investors shorting Acurx Pharmaceuticals?: Acurx Pharmaceuticals saw a increase in short interest in March. As of March 31st, there was short interest totaling 337,400 shares, an increase of 14.6% from the March 15th total of 294,500 shares. Based on an average daily volume of 169,100 shares, the days-to-cover ratio is presently 2.0 days. Approximately 2.8% of the company's shares are short sold.
View Acurx Pharmaceuticals' Short Interest.
When is Acurx Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024.
View our ACXP earnings forecast.

How were Acurx Pharmaceuticals' earnings last quarter?: Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) announced its quarterly earnings results on Friday, March, 15th. The company reported ($0.38) EPS for the quarter, missing the consensus estimate of ($0.26) by $0.12.
When did Acurx Pharmaceuticals IPO?: Acurx Pharmaceuticals (ACXP) raised $15 million in an IPO on Friday, June 25th 2021. The company issued 2,500,000 shares at $5.00-$7.00 per share. Alexander Capital, L.P. and Network 1 Financial Securities served as the underwriters for the IPO.
Who are Acurx Pharmaceuticals' major shareholders?: Acurx Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include NBC Securities Inc. (0.09%). Insiders that own company stock include Carl Sailer, David P Luci and Robert J Deluccia.
View institutional ownership trends.
How do I buy shares of Acurx Pharmaceuticals?: Shares of ACXP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ACXP) was last updated on 4/17/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial